3650 results for «730»
3650 results
Refining management of NSTEMI
21 May 2026 – From EuroPCR 2026
This session refines NSTEMI management by exploring advanced diagnostic tools, risk stratification, and tailored revascularization strategies, including bleeding risk assessment and dual antiplatelet therapy considerations.
Aneurysms and fistulas: contemporary approaches
21 May 2026 – From EuroPCR 2026
Focus on contemporary approaches to coronary aneurysms and fistulas, presenting complex interventional techniques and case-based strategies to overcome anatomical challenges and ensure effective treatment.
How to achieve coronary patency during TAVI
21 May 2026 – From EuroPCR 2026
This session addresses techniques to achieve coronary artery patency during transcatheter aortic valve implantation (TAVI), highlighting advanced procedural approaches and management of high-risk anatomical scenarios.
Sealing the deal: catheter based solutions for aortic disease
21 May 2026 – From EuroPCR 2026
Examine catheter-based solutions for aortic disease management, featuring innovative approaches to preserving branch vessels, managing vascular complications, and repairing challenging aneurysms with endografts and occluders.
Femoral artery pseudoaneurysm expansion managed through subcutaneous fat embolization
06 Apr 2021
Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.
Author
PCR @ TCT 2024 - Get the international perspective!
27 Oct 2024
Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement
18 Sep 2022
Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
